PDF下载 ( 1198 KB)
Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)
-
摘要:
为了实现世界卫生组织提出的"2030年消除病毒性肝炎作为重大公共卫生威胁"的目标,中华医学会感染病学分会和肝病学分会于2019年组织国内有关专家,以国内外慢性乙型肝炎病毒感染的基础、临床、预防研究进展为依据,结合现阶段我国的实际情况,更新形成了《慢性乙型肝炎防治指南(2019年版)》,为慢性乙型肝炎的预防、诊断和治疗提供重要依据。
Abstract:In order to achieve the goal of “eliminating viral hepatitis as a major public health threat by 2030”established by the World Health Organization,Chinese Society of Infectious Diseases and Chinese Society of Hepatology,Chinese Medical Association,organized related experts in 2019 to update and develop Guidelines for the prevention and treatment of chronic hepatitis B( version 2019),with reference to the advances in the basic and clinical research on chronic hepatitis B virus infection in China and foreign countries and the actual conditions in China,in order to provide an important basis for the prevention,diagnosis,and treatment of chronic hepatitis B.
-
Key words:
- hepatitis B,chronic /
- drug therapy /
- universal precautions /
- practice guidelines as topic
-
[1] WHO. Global hepatitis report,2017[EB/OL].[2019-11-06]. https://www. who. int/hepatitis/publications/globalhepatitis-report2017/en/． [2] CUI F,SHEN L,LI L,et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy,China[J].Emerg Infect Dis,2017,23(5):765-772. [3] LIU J,LIANG W,JING W,et al. Countdown to 2030:Eliminating hepatitis B disease,China[J]. Bull World Health Organ,2019,97(3):230-238. [4] XU Y,LIU H,WANG Y,et al. The next step in controlling HBV in China[J/OL]. BMJ,2013,347:f4503. [5] LU Y,ZHU FC,LIU JX,et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources:A large prospective cohort study in China[J]. Vaccine,2017,35(48 Pt B):6627-6633. [6] TERRAULT NA,LOK ASF,MCMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599. [7] SCHILLIE S,VELLOZZIC,REINGOLD A,et al. Prevention of hepatitis B virus infection in the United States:Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Recomm Rep,2018,67(1):1-31. [8] WHO. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[M]. Geneva:World Health organization,2015. [9] National Health and Family Planning Commission,National Development and Reform Commission,Ministry of Education,et al. Action plan for the prevention and treatment of viral hepatitis in China(2017—2020)[J]. Chin J Viral Dis,2018,8(1):1-5.(in Chinese)国家卫生计生委，国家发展改革委，教育部，等．中国病毒性肝炎防治规划(2017-2020年)[J]．中国病毒病杂志，2018,8(1):1-5. [10] World Health Organization. Hepatitis B vaccines:WHO position paper,July 2017-Recommendations[J]. Vaccine,2019,37(2):223-225. [11] BRUCE MG,BRUDEN D,HURLBURT D,et al. Antibody levels and protection after hepatitis B vaccine:Results of a 30-year follow-up study and response to a booster dose[J]. J Infect Dis,2016,214(1):16-22. [12] LEVY M,KOREN G. Hepatitis B vaccine in pregnancy:Maternal and fetal safety[J]. Am J Perinatol,1991,8(3):227-232. [13] MORO PL,ZHETEYEVA Y,BARASH F,et al. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System(VAERS),1990-2016[J]. Vaccine,2018,36(1):50-54. [14] SHEFFIELD JS,HICKMAN A,TANG J,et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy[J]. Obstet Gynecol,2011,117(5):1130-1135. [15] YAN H,ZHONG G,XU G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J/OL]. Elife,2012,1:e00049. [16] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462. [17] LU FM,WANG J,ZHUANG H. Potential clinical significance of serum HBV RNA virus-like particles[J]. Chin J Hepatol,2016,24(9):641-642.(in Chinese)鲁凤民，王杰，庄辉．HBV RNA病毒样颗粒的潜在临床意义[J]．中华肝脏病杂志，2016,24(9):641-642. [18] LU FM,DOU XG,ZHANG WH,et al. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. J Clin Hepatol,2018,34(5):934-938.(in Chinese)鲁凤民，窦晓光，张文宏，等．慢性乙型肝炎患者血清HBV RNA检测的临床意义[J]．临床肝胆病杂志，2018,34(5):934-938. [19] MCNAUGHTON AL,D’ARIENZO V,ANSARI MA,et al. Insights from deep sequencing of the HBV genome-unique,tiny,and misunderstood[J]. Gastroenterology,2019,156(2):384-399. [20] LIN CL,KAO JH. The clinical implications of hepatitis B virus genotype:Recent advances[J]. J Gastroenterol Hepatol,2011,26(Suppl 1):123-130. [21] LIVINGSTON SE,SIMONETTI JP,BULKOW LR,et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A,B,C,D,and F[J]. Gastroenterology,2007,133(5):1452-1457. [22] YU MW,YEH SH,CHEN PJ,et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma:A prospective study in men[J]. J Natl Cancer Inst,2005,97(4):265-272. [23] TANG LSY,COVERT E,WILSON E,et al. Chronic hepatitis B infection:A review[J]. JAMA,2018,319(17):1802-1813. [24] INDOLFI G,EASTERBROOK P,DUSHEIKO G,et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol,2019,4(6):466-476. [25] NAYAGAM S,THURSZ M,SICURI E,et al. Requirements for global elimination of hepatitis B:A modelling study[J]. Lancet Infect Dis,2016,16(12):1399-1408. [26] LIU JF,YAO NJ,CHEN TY,et al. Prevalence of mother-tochild transmission of hepatitis B virus:A systematic review and meta-analysis[J]. J Hepatol,2019,70(Suppl 1):e123-e124. [27] Chinese Society of Infectious Diseases,Chinese Medical Association; Chinese GRADE Center. Guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus in China(version 2019)[J]. Chin J Infect Dis,2019,37(7):388-396.(in Chinese)中华医学会感染病学分会，GRADE中国中心．中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]．中华传染病杂志，2019,37(7):388-396. [28] LIAW YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(Suppl 1):100-107. [29] FANNING GC,ZOULIM F,HOU J,et al. Therapeutic strategies for hepatitis B virus infection:Towards a cure[J]. Nat Rev Drug Discov,2019,18(11):827-844. [30] HUI CK,LEUNG N,YUEN ST,et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology,2007,46(2):395-401. [31] LIAW YF. Hepatitis flares and hepatitis B e antigen seroconversion:Implication in anti-hepatitis B virus therapy[J]. J Gastroenterol Hepatol,2003,18(3):246-252. [32] CHU CM,HUNG SJ,LIN J,et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med,2004,116(12):829-834. [33] CHU CM,LIAW YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers[J]. Clin Infect Dis,2012,54(1):88-90. [34] CHU CM,LIAW YF. Hepatitis B surface antigen seroclearance during chronic HBV infection[J]. Antivir Ther,2010,15(2):133-143. [35] FATTOVICH G,BORTOLOTTI F,DONATO F. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors[J]. J Hepatol,2008,48(2):335-352. [36] CHEN YC,CHU CM,LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology,2010,51(2):435-444. [37] PARK BK,PARK YN,AHN SH,et al. Long-term outcome of chronic hepatitis B based on histological grade and stage[J]. J Gastroenterol Hepatol,2007,22(3):383-388. [38] LIN SM,YU ML,LEE CM,et al. Interferon therapy in HBe Ag positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol,2007,46(1):45-52. [39] CHU CM,LIAW YF. Hepatitis B virus-related cirrhosis:Natural history and treatment[J]. Semin Liver Dis,2006,26(2):142-152. [40] CHEN YC,CHU CM,YEH CT,et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:A long-term follow-up study[J]. Hepatol Int,2007,1(1):267-273. [41] HSU YS,CHIEN RN,YEH CT,et al. Long-term outcome after spontaneous HBe Ag seroconversion in patients with chronic hepatitis B[J]. Hepatology,2002,35(6):1522-1527. [42] McMAHON BJ,HOLCK P,BULKOW L,et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus[J]. Ann Intern Med,2001,135(9):759-768. [43] FATTOVICH G,GIUSTINA G,SCHALM SW,et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis[J]. Hepatology,1995,21(1):77-82. [44] FATTOVICH G. Natural history and prognosis of hepatitis B[J]. Semin Liver Dis,2003,23(1):47-58. [45] TSENG TC,LIU CJ,YANG HC,et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads[J]. Hepatology,2013,57(2):441-450. [46] TSENG TC,LIU CJ,YANG HC,et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J]. Gastroenterology,2012,142(5):1140-1149,e3. [47] ZHANG Z,ZHANG JY,WANG LF,et al. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection[J]. J Gastroenterol Hepatol,2012,27(2):223-230. [48] DANDRI M,LOCARNINI S. New insight in the pathobiology of hepatitis B virus infection[J]. Gut,2012,61(Suppl 1):i6-i17. [49] ISOGAWA M,TANAKA Y. Immunobiology of hepatitis B virus infection[J]. Hepatol Res,2015,45(2):179-189. [50] GUIDOTTI LG,CHISARI FV. Noncytolytic control of viral infections by the innate and adaptive immune response[J]. Annu Rev Immunol,2001,19:65-91. [51] BERTOLETTI A,FERRARI C. Innate and adaptive immune responses in chronic hepatitis B virus infections:Towards restoration of immune control of viral infection[J]. Gut,2012,61(12):1754-1764. [52] CORNBERG M,WONG VW,LOCARNINI S,et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol,2017,66(2):398-411. [53] HOU JL,ZHAO W,LEE C,et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print] [54] KIM JH,SINN DH,KANG W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology,2017,66(2):335-343. [55] WIEGAND J,HASENCLEVER D,TILLMANN HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence[J]. Antivir Ther,2008,13(2):211-220. [56] NI YH,CHANG MH,WANG KJ,et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma[J]. Gastroenterology,2004,127(6):1733-1738. [57] CHU CJ,HUSSAIN M,LOK AS. Hepatitis B virus genotype B is associated with earlier HBe Ag seroconversion compared with hepatitis B virus genotype C[J]. Gastroenterology,2002,122(7):1756-1762. [58] WATANABE K,TAKAHASHI T,TAKAHASHI S,et al. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations[J]. J Gastroenterol Hepatol,2005,20(3):441-449. [59] RAJORIYA N,COMBET C,ZOULIM F,et al. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?[J]. J Hepatol,2017,67(6):1281-1297. [60] JIA W,SONG LW,FANG YQ,et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B:A prospective observational study[J]. Medicine(Baltimore),2014,93(29):e322. [61] SONG LW,LIU PG,LIU CJ,et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect,2015,21(2):197-203. [62] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320. [63] HOU FQ,SONG LW,YUAN Q,et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBe Ag-positive chronic hepatitis B patients receiving peginterferon[J]. Theranostics,2015,5(3):218-226. [64] ZHOU J,SONG L,ZHAO H,et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase[J]. Sci Rep,2017,7(1):2747. [65] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710. [66] FAN R,ZHOU B,XU M,et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print] [67] WONG DK,SETO WK,CHEUNG KS,et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA[J]. Liver Int,2017,37(7):995-1001. [68] MARTINOT-PEIGNOUX M,LAPALUS M,MAYLIN S,et al.Baseline HBs Ag and HBcrAg titres allow peginterferon-based‘precision medicine’in HBe Ag-negative chronic hepatitis B patients[J]. J Viral Hepat,2016,23(11):905-911. [69] HONDA M,SHIRASAKI T,TERASHIMA T,et al. Hepatitis B virus(HBV)core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma[J]. J Infect Dis,2016,213(7):1096-1106. [70] CHUAYPEN N,POSUWAN N,PAYUNGPORN S,et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBe Ag-positive chronic hepatitis B[J]. Liver Int,2016,36(6):827-836. [71] KWO PY,COHEN SM,LIM JK. ACG clinical guideline:Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol,2017,112(1):18-35. [72] WANG K,LIN W,KUANG Z,et al. Longitudinal change of body mass index is associated with alanine aminotransferase elevation after complete viral suppression in chronic hepatitis B patients[J]. J Infect Dis,2019,220(9):1469-1476. [73] AMADDEO G,CAO Q,LADEIRO Y,et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas[J]. Gut,2015,64(5):820-829. [74] SEO SI,KIM HS,KIM WJ,et al. Diagnostic value of PIVKAII and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J]. World J Gastroenterol,2015,21(13):3928-3935. [75] WAI CT,CHENG CL,WEE A,et al. Non-invasive models for predicting histology in patients with chronic hepatitis B[J].Liver Int,2006,26(6):666-672. [76] KIM WR,BERG T,ASSELAH T,et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol,2016,64(4):773-780. [77] DONG XQ,WU Z,ZHAO H,et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients[J]. J Viral Hepat,2019,26(2):297-307. [78] SONNEVELD MJ,BROUWER WP,CHAN HL,et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B:Results from the SONIC-B study[J]. Lancet Gastroenterol Hepatol,2019,4(7):538-544. [79] LEMOINE M,SHIMAKAWA Y,NAYAGAM S,et al. The gamma-glutamyl transpeptidase to platelet ratio(GPR)predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut,2016,65(8):1369-1376. [80] CHEN YP,HU XM,LIANG XE,et al. Stepwise application of fibrosis index based on four factors,red cell distribution width-platelet ratio,and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection[J]. J Gastroenterol Hepatol,2018,33(1):256-263. [81] YAO M,WANG L,YOU H,et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B[J]. Clin Chim Acta,2019,493:92-97. [82] WANG L,LIU T,ZHOU J,et al. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy[J]. Hepatol Res,2018,48(3):e283-e290. [83] YAN L,DENG Y,ZHOU J,et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection,2018,46(3):385-393. [84] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol,2015,63(1):237-264. [85] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association,et al. Consensus on clinical application of transient elastography detecting liver fibrosis:A 2018 update[J]. Chin J Hepatol,2019,27(3):182-191.(in Chinese)中国肝炎防治基金会，中华医学会感染病学分会，中华医学会肝病学分会，等．瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]．中华肝脏病杂志，2019,27(3):182-191. [86] CHEN YP,LIANG XE,DAI L,et al. Improving transient elastography performance for detecting hepatitis B cirrhosis[J].Dig Liver Dis,2012,44(1):61-66. [87] CHEN YP,LIANG XE,ZHANG Q,et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J]. J Gas troenterol Hepatol,2012,27(7):1219-1226. [88] CHAN HL,WONG GL,CHOI PC,et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography(Fibroscan)for liver fibrosis in chronic hepatitis B[J]. J Viral Hepat,2009,16(1):36-44. [89] LIANG XE,ZHONG C,HUANG L,et al. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers[J]. J Gastroenterol Hepatol,2017,32(2):459-465. [90] SCOTT DR,LEVY MT. Liver transient elastography(Fibroscan):A place in the management algorithms of chronic viral hepatitis[J]. Antivir Ther,2010,15(1):1-11. [91] WU Z,DONG X,WANG G,et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J]. J Viral Hepat,2019,26(2):287-296. [92] JIA J,HOU J,DING H,et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J]. J Gastroenterol Hepatol,2015,30(4):756-762. [93] FETZER DT,RODGERS SK,SEOW JH,et al. Ultrasound evaluation in patients at risk for hepatocellular carcinoma[J]. Radiol Clin North Am,2019,57(3):563-583. [94] ELSAYES KM,KIELAR AZ,CHERNYAK V,et al. LI-RADS:A conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance[J]. J Hepatocell Carcinoma,2019,6:49-69. [95] KNODELL RG,ISHAK KG,BLACK WC,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology,1981,1(5):431-435. -
本文二维码
计量
- 文章访问数: 8169
- HTML全文浏览量: 734
- PDF下载量: 3419
- 被引次数: 0
下载:
